Hikma Pharmaceuticals
Coverage of Hikma Pharmaceuticals in the Nexus archive.
- Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
The Supreme Court ruled that Amarin Pharma has not sufficiently proven that Hikma Pharmaceuticals' generic version of icosapent ethyl (Vascepa) infringes on its patents. The decision centers on a 'Skinny Label' case involving the heart drug.
- STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
The Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe on Amarin's patents, supporting the use of 'skinny labeling' by generic drugmakers. This decision overturns a lower court ruling and reduces legal risks for generic companies marketing drugs for specific uses to avoid patent infringement lawsuits.
- How a Supreme Court fight over fish oil could raise your prescription drug costs
The Supreme Court is set to hear Hikma v. Amarin, a patent dispute over fish oil-based drugs that could increase prescription drug costs for patients and disrupt generic drug company operations. The case centers on whether Amarin's patent for Vascepa (a fish oil drug) was invalidated by prior art, which could affect how generic manufacturers navigate patent challenges.